A phase III study of Eryaspase as second line treatment for patients with metastatic pancreatic cancer
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2017
At a glance
- Drugs ERY-ASP (Primary)
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors ERYtech Pharma
- 06 Nov 2017 According to an ERYTECH media release, this trial is expected to initiate in the third quarter of 2018.
- 11 Sep 2017 According to an ERYtech Pharma media release, the company expects the potential launch of this study over next twelve months.
- 11 Sep 2017 According to an ERYtech Pharma media release, the company expects to discuss the design of this potential phase 3 study with the U.S. FDA in the coming weeks (scheduled for October) and the Committee for Medicinal Products for Human Use (CHMP) before the end of the year (later in 2017).